PT  - JOURNAL ARTICLE
AU  - Zou, Zheng-Qiang
AU  - Chen, Jia-Jia
AU  - Feng, Hong-Fang
AU  - Cheng, Yu-Fang
AU  - Wang, Hai-Tao
AU  - Zhou, Zhong-Zhen
AU  - Guo, Hai-Biao
AU  - Zheng, Wenhua
AU  - Xu, Jiang-Ping
TI  - Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF-<em>κ</em>B Inhibition
AID  - 10.1124/jpet.116.239608
DP  - 2017 Jul 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 67--77
VI  - 362
IP  - 1
4099  - http://jpet.aspetjournals.org/content/362/1/67.short
4100  - http://jpet.aspetjournals.org/content/362/1/67.full
SO  - J Pharmacol Exp Ther2017 Jul 01; 362
AB  - Overactivation of microglia contributes to the induction of neuroinflammation, which is highly involved in the pathology of many neurodegenerative diseases. Phosphodiesterase 4 (PDE4) represents a promising therapeutic target for anti-inflammation; however, the dose-limiting side effects, such as nausea and emesis, have impeded their clinic application. FCPR03, a novel selective PDE4 inhibitor synthesized in our laboratory, shows little or no emetic potency; however, the anti-inflammatory activities of FCPR03 in vitro and in vivo and the molecular mechanisms are still not clearly understood. This study was undertaken to delineate the anti-inflammatory effects of FCPR03 both in vitro and in vivo and explore whether these effects are regulated by PDE4-mediated signaling pathway. BV-2 microglial cells stimulated by lipopolysaccharide (LPS) and mice injected i.p. with LPS were established as in vitro and in vivo models of inflammation. Our results showed that FCPR03 dose dependently suppressed the production of tumor necrosis factor α, interleukin-1β, and iinterleukin-6 in BV-2 microglial cells treated with LPS. The role of FCPR03 in the production of proinflammatory factors was reversed by pretreatment with protein kinase A (PKA) inhibitor H89. In addition, FCPR03 reduced the levels of proinflammatory factors in the hippocampus and cortex of mice injected with LPS. Our results further demonstrated that FCPR03 effectively increased the production of cAMP, promoted cAMP response element binding protein (CREB) phosphorylation, and inhibited nuclear factor κB (NF-κB) activation both in vitro and in vivo. Our findings suggest that FCPR03 inhibits the neuroinflammatory response through the activation of cAMP/PKA/CREB signaling pathway and NF-κB inhibition.